#biotech

Last 24h 📊 Neutral 📈3 📉1 📊4

Last 7 Days 📊 Neutral 📈11 📉4 📊21

Last 30 Days 📊 Neutral 📈79 📉9 📊81

News 📈 Stocks

AAZ Revenue Triples as Small-Cap Miners and Builders Report Growth

September 21, 2026 (50 days ago)

Anglo Asian Mining triples revenue, Eco Buildings signs a massive 10,000-home deal in The Gambia, and Iofina reports record iodine volumes in…

AAZ IOF ECOB +1

🌍 EUROPE Read More →

News 📈 Stocks

Thermo Fisher Rallies 8% as Biotech Funding Recovery Drives UBS Upgrade

September 20, 2026 (51 days ago)

Thermo Fisher gains momentum on strong organic growth and biotech recovery, while Becton Dickinson struggles with regulatory hurdles and higher short interest.

TMO BDX MDT +2

🌍 US Read More →

News 📈 Stocks

GSK China Deals Surge as Biotech IPOs Hit $300M Milestone

September 19, 2026 (52 days ago)

GSK accelerates China-focused oncology licensing, Electra Therapeutics joins a record-setting cohort of large-scale biotech IPOs, and Scholar Rock faces a sell-the-news reaction…

SRRK GSK ELTA +4

🌍 GLOBAL Read More →

News 📈 Stocks

Caris Life Sciences Rallies 10% as Precision Oncology Sector Gains Momentum

September 19, 2026 (52 days ago)

Caris Life Sciences shares climbed 10% in a sector-wide rally, leaving the stock trading above analyst price targets as investors weigh decelerating…

CAI TEM MRNA

🌍 AMERICAS Read More →

Earnings 📈 Stocks

Innate Pharma Extends Cash Runway to 2028 Following $75M Sobi Partnership

September 19, 2026 (52 days ago)

Innate Pharma strengthens its balance sheet with a $75M Sobi payment and $30M equity raise, supporting a robust clinical pipeline that includes…

IPHA SOBI

🌍 EUROPE Read More →

News 📈 Stocks

Neurocrine Biosciences Posts 39% Revenue Growth Amid KINECT-PRO Clinical Wins

September 19, 2026 (52 days ago)

Neurocrine Biosciences balances robust 39% revenue growth and positive clinical data for INGREZZA against a tightened balance sheet following its $2.9 billion…

NBIX SLNO

🌍 AMERICAS Read More →

News 📈 Stocks

Novartis Shares Plunge 11% After $32 Billion Market Value Wipeout

September 19, 2026 (52 days ago)

Novartis stock plummeted 10.9% following the failure of its del-desiran trial, triggering a sector-wide selloff in muscular-disease stocks including Sarepta and Dyne…

NVS SRPT DYN

🌍 EUROPE Read More →

News 📈 Stocks

Ascendis Pharma Regains TransCon Rights After Novo Nordisk Collaboration Ends

September 19, 2026 (52 days ago)

Ascendis Pharma reclaims full control of its TransCon metabolic pipeline from Novo Nordisk, trading partnership security for the potential to capture higher…

ASND NVO

🌍 EUROPE Read More →

News 📈 Stocks

North Immunology to Go Public via $180M Reverse Merger with Aethlon Medical

September 18, 2026 (52 days ago)

North Immunology secures $180 million and a Nasdaq listing via a reverse merger with Aethlon Medical to advance its dual-pathway inflammatory drug,…

NRTX AEMD KYMR +3

🌍 AMERICAS Read More →

News 📈 Stocks

Biotech IPO Market Faces Scrutiny as 8 Firms Seek Capital for Clinical Trials

September 18, 2026 (52 days ago)

Investors are prioritizing clinical-stage biotechs with proven potential, as eight companies navigate the IPO process with varying degrees of market readiness and…

Grifols Electra Therapeutics Tarsier Therapeutics +6

🌍 GLOBAL Read More →

News 📈 Stocks

Amgen Shares Offer Defensive Hedge Amid Market Volatility and Economic Risks

September 18, 2026 (53 days ago)

Amgen remains a defensive staple for investors, leveraging a strong dividend yield and diversified drug pipeline to navigate broader economic instability and…

AMGN NVS NVDA

🌍 AMERICAS Read More →

News 📈 Stocks

Merck Shares Rally 11% on Positive Phase 3 mRNA Cancer Therapy Results

September 17, 2026 (53 days ago)

Merck stock surges 11% following breakthrough Phase 3 cancer trial results with Moderna, while the company maintains a strong dividend profile and…

MRK MRNA GOOGL +1

🌍 AMERICAS Read More →